Segall Bryant & Hamill, LLC Biocryst Pharmaceuticals Inc Transaction History
Segall Bryant & Hamill, LLC
- $6.35 Billion
- Q1 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 1,330,314 shares of BCRX stock, worth $14.7 Million. This represents 0.16% of its overall portfolio holdings.
Number of Shares
1,330,314
Previous 1,422,196
6.46%
Holding current value
$14.7 Million
Previous $10.7 Million
6.7%
% of portfolio
0.16%
Previous 0.15%
Shares
13 transactions
Others Institutions Holding BCRX
# of Institutions
286Shares Held
169MCall Options Held
728KPut Options Held
989K-
Vanguard Group Inc Valley Forge, PA21.7MShares$239 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$220 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$131 Million1.3% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$100 Million4.33% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY8.14MShares$89.8 Million1.52% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $2.05B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...